Application of PAR hydrolase inhibitor (PDD) in preparation of medicine for treating peripheral neuropathy related to DNA damage
By using PAR hydrolase inhibitors to inhibit PARG enzyme, the DNA damage and axonal degeneration caused by MORC2 gene mutation in periomyomatosis was solved, and a new treatment plan for periomyomatosis was provided, which significantly improved the patient's pathological status.
Patent Information
- Application Number
- CN202411457061.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-18
- Publication Date
- 2024-11-29
AI Technical Summary
The mechanism of DNA damage repair caused by MORC2 musculosomes (CMT2Z) patients with peroneal mutations is unknown, the existing treatment methods are limited, and there is a lack of targeted treatment options.
PAR hydrolase inhibitors, such as PDD00017273, esacridine lactate, etc., are used to inhibit PARG enzymes, reduce DNA damage and axonal degeneration, and provide new drug strategies for the treatment of peroneal muscular atrophy.
It significantly improves DNA damage and axonal degeneration caused by MORC2 mutations, provides potential drug development ideas for the treatment of peroneal muscular atrophy, and has good clinical application prospects.
Smart Images

Figure CN119033940A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and in particular, relates to the use of a PAR hydrolase inhibitor (PDD) in the preparation of a drug for treating DNA damage-related peripheral neuropathy. Background Art
[0002] Charcot-Marie-Tooth Disease (CMT), also known as hereditary motor and sensory neuropathy (HMSN), is a group of the most common monogenic hereditary peripheral neuropathies with a prevalence of approximately 1 / 2500. It has significant clinical and genetic heterogeneity and is characterized by progressive distal muscle weakness and atrophy, sensory deficits, impaired tendon reflexes, and foot deformities. Clinically, CMT is divided into three subtypes based on neuroelectrophysiological criteria and pathological characteristics: first, CMT type 1, also known as demyelinating type, is mainly manifested by peripheral nerve myelin formation disorders and demyelination, and its significant neuroelectrophysiological feature is that the motor nerve conduction velocity (MNCV) of the median nerve is less than 38m / s; second, CMT type 2 or axonal type, which is characterized by axonal degeneration, the median nerve MNCV is greater than 38m / s, and is accompanied by a significant decrease in the amplitude of compound motor action potentials (CMAP); finally, intermediate CMT (ICMT), ICMT has both peripheral nerve demyelination and axonal degeneration, and the median nerve MNCV is between 25-45m / s.
[0003] In 2016, Teresa Sevilla et al. identified the p.R252 mutation and p.S87L mutation of the MORC2 (Microrchidia family CW-type zinc finger 2) gene in pedigrees and sporadic cases of CMT2, and confirmed the pathogenicity of these mutations through genetic and computer simulation analysis, indicating that MORC2 is a new pathogenic gene of CMT2. This subtype was subsequently named CMT2Z. In 2017, the inventor team reported new MORC2 mutations (p.Q400R and p.D466N) in the Chinese CMT2 population, and found the MORC2 hotspot mutation p.S87L in a patient with a severe phenotype (SMA-like). CMT2Z is autosomal dominant, mainly manifested as motor and sensory neuropathy with axonal involvement, clinically characterized by onset in childhood or early adulthood, progressive distal limb weakness, sensory loss, loss of tendon reflexes, and high arches, but with the progression of the disease, significant proximal muscle weakness may also occur. CMT2 (axonal CMT) is caused by peripheral nerve axon degeneration, leading to motor and sensory nerve dysfunction. The high genetic heterogeneity of CMT2 suggests that the same phenotype of peripheral nerve axon degeneration has different intrinsic molecular mechanisms. A deep understanding of the molecular pathological mechanism of specific pathogenic genes is of vital value in promoting the development of targeted treatments for CMT2.
[0004] As one of the main subtypes of CMT2, CMT2Z seriously affects the quality of life of patients. Targeted drug development is expected to alleviate the symptoms of CMT2Z patients, improve the quality of life of patients and reduce the social burden. MORC2 is the pathogenic gene of CMT2Z. Missense mutations can cause severe neuropathy. The encoded MORC2 protein has multiple functions, one of its main biological functions is to maintain the balance of DNA damage repair. However, the potential mechanism by which MORC2 pathogenic variants cause CMT2Z is still unclear. The related clinical phenotypes caused by different mutations in the MORC2 gene are highly heterogeneous. Clarifying the differences and commonalities in the pathogenic mechanisms between different mutations will provide an effective strategy for precision medicine of CMT2Z. This study intends to clarify the effects of MORC2 pathogenic variants on neurons at the iPSCs-MNs level, explore the MORC2-related DNA damage repair mechanism, and find small molecule drugs targeting the DNA damage repair mechanism, opening up new ideas for potential treatment options for CMT2Z. Summary of the invention
[0005] In view of this, the object of the present invention is to provide a use of a PAR hydrolase inhibitor (PDD) in the preparation of a drug for treating DNA damage-related peripheral neuropathy.
[0006] The present invention adopts the following technical solutions to achieve the above-mentioned invention objectives:
[0007] The first aspect of the present invention provides the use of a PAR hydrolase inhibitor in the preparation of a medicament for treating and / or preventing Charcot-Marie-Tooth disease.
[0008] Further, the PAR hydrolase inhibitor includes PDD00017273, ethacridine lactate, PDD00031705, COH34, PDD00017238, JA2131, PDD00017272, PARG-IN-4 and / or ethacridine;
[0009] Optionally, the PAR hydrolase inhibitor is PDD00017273.
[0010] Furthermore, the Charcot-Marie-Tooth disease includes demyelinating Charcot-Marie-Tooth disease, axonal Charcot-Marie-Tooth disease and / or intermediate Charcot-Marie-Tooth disease;
[0011] Optionally, the Charcot-Marie-Tooth disease is axonal Charcot-Marie-Tooth disease; optionally, the drug further comprises a pharmaceutically acceptable excipient; optionally, the pharmaceutically acceptable excipient includes a diluent, a binder, a surfactant, a wetting agent, an adsorption carrier, a lubricant, a filler and / or a disintegrant; optionally, the dosage form of the drug includes an injection, a tablet, a capsule, a powder, a granule, an ointment, a suppository, an inhalant, a gel, a microsphere and / or an aerosol.
[0012] In a specific embodiment of the present invention, the PAR hydrolase inhibitor is PDD00017273, with a molecular formula of C 23 H 26 N 6 O 4 S 2 , molecular weight 514.62, structural formula as shown in formula (I), CAS number 1945950-21-9, purchased from Selleck. PDD00017273 is a potent and selective poly(ADP ribose) glycohydrolase (PARG) inhibitor (PAR hydrolase inhibitor) with an IC50 of 26nM. Its selectivity for PARG (PAR hydrolase) is more than 350 times higher than that for other ion channels, enzymes and receptors (such as PARP1 and ARH3).
[0013]
[0014] In some embodiments of the present invention, the PAR hydrolase inhibitor is ethacridine lactate, with a molecular formula of C 18 H 21 N 3 O 4, molecular weight is 343.38, structural formula is shown in formula (II), CAS number is 1837-57-6. Ethacridine lactate is an aromatic organic compound based on acridine, which can be used as a preservative. Ethacridine lactate is also a poly(ADP-ribose)glycohydrolase(PARG) inhibitor.
[0015]
[0016] In some embodiments of the present invention, the PAR hydrolase inhibitor is PDD00031705, with a molecular formula of C 20 H 22 N 6 O 3 S 3 , molecular weight is 490.62, structural formula is shown in formula (III), CAS number is 2032096-45-8. PDD00031705 is a cell-inactive poly(adenosine diphosphate ribose) hydrolase (PARG) inhibitor with a benzimidazolone core structure.
[0017]
[0018] In some embodiments of the present invention, the PAR hydrolase inhibitor is COH34, with a molecular formula of C 18 H 15 NOS, molecular weight is 293.38, structural formula is shown in formula (IV), CAS number is 906439-72-3. COH34 is an effective and specific poly (ADP-ribose) hydrolase (PARG) inhibitor.
[0019]
[0020] In some embodiments of the present invention, the PAR hydrolase inhibitor is PDD00017238, with a molecular formula of C 19 H 20 N 6 O 3 S 3 , molecular weight 476.60, structural formula as shown in formula (V), CAS number 1952247-05-0. PDD00017238 is an effective poly (adenosine diphosphate ribose) hydrolase (PARG) inhibitor.
[0021]
[0022] In some embodiments of the present invention, the PAR hydrolase inhibitor is JA2131, with a molecular formula of C 13 H 19N 5 O 2 S 2 , molecular weight is 341.45, structural formula is shown in formula (VI), CAS number is 6505-99-3. JA2131 is a small molecule inhibitor targeting poly ADP ribose glycohydrolase (PARG) (IC50 = 0.4 μM).
[0023]
[0024] In some embodiments of the present invention, the PAR hydrolase inhibitor is PDD00017272, with a molecular formula of C 23 H 25 N 5 O 4 S 3 , molecular weight is 531.67, structural formula is shown in formula (VII), CAS number is 1945950-20-8. PDD00017272 is an effective poly (adenosine diphosphate ribose) hydrolase (PARG) inhibitor.
[0025]
[0026] In some embodiments of the present invention, the PAR hydrolase inhibitor is PARG-IN-4, with a molecular formula of C 20 H 25 F 2 N 7 O 2 S 2 , molecular weight is 497.59, structural formula is shown in formula (VIII), CAS number is 2988890-20-4. PARG-IN-4 is an orally active and cell permeable PARG inhibitor.
[0027]
[0028] In some embodiments of the present invention, the PAR hydrolase inhibitor is ethacridine, with a molecular formula of C 15 H 15 N 3 O, molecular weight is 253.30, structural formula is shown in formula (IX), CAS number is 442-16-0. Ethacridone is an inhibitor of poly (ADP-ribose) glycohydrolase (PARG).
[0029]
[0030] In the present invention, the Charcot-Marie-Tooth disease (CMT) includes demyelinating Charcot-Marie-Tooth disease (CMT1), axonal Charcot-Marie-Tooth disease (CMT2) and / or intermediate Charcot-Marie-Tooth disease (ICMT).
[0031] In some embodiments, the present invention has no particular restrictions on the pharmaceutically acceptable excipients, which refer to any pharmaceutically acceptable excipients or vehicles well known in the pharmaceutical field, such as liquid or solid fillers, diluents, excipients, solvents or encapsulating materials. In terms of compatibility with other ingredients and harmlessness to patients, each excipient or vehicle should be "acceptable".
[0032] Some examples of pharmaceutically acceptable excipients include, but are not limited to, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetate; tragacanth powder; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols such as propylene glycol; polyols such as glycerol, sorbitol, mannitol and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethanol; phosphate buffered saline; and other nontoxic and compatible substances for pharmaceutical preparations.
[0033] A second aspect of the present invention provides a pharmaceutical composition for treating and / or preventing Charcot-Marie-Tooth disease.
[0034] Furthermore, the pharmaceutical composition comprises a therapeutically and / or preventively effective amount of a PAR hydrolase inhibitor.
[0035] Further, the PAR hydrolase inhibitor includes PDD00017273, ethacridine lactate, PDD00031705, COH34, PDD00017238, JA2131, PDD00017272, PARG-IN-4 and / or ethacridine;
[0036] Optionally, the PAR hydrolase inhibitor is PDD00017273; optionally, the Charcot-Marie-Tooth disease includes demyelinating Charcot-Marie-Tooth disease, axonal Charcot-Marie-Tooth disease and / or intermediate Charcot-Marie-Tooth disease; optionally, the Charcot-Marie-Tooth disease is axonal Charcot-Marie-Tooth disease.
[0037] In some embodiments, the pharmaceutical composition may further comprise other drugs that can be used to treat and / or prevent, or assist in the treatment and / or assist in the prevention of Charcot-Marie-Tooth disease.
[0038] In the present invention, the therapeutically effective amount refers to an amount sufficient to provide a therapeutic benefit in the process of treating a disease, disorder or condition, or to delay or minimize one or more symptoms associated with the disease, disorder or condition. The therapeutically effective amount of a compound refers to the amount of a therapeutic agent that provides a therapeutic benefit in the process of treating a disease, disorder or condition when used alone or in combination with other therapies.
[0039] In the present invention, the preventive effective amount refers to an amount sufficient to prevent a disease, disorder or condition, or an amount sufficient to prevent one or more symptoms associated with a disease, disorder or condition, or an amount to prevent the recurrence of a disease, disorder or condition. A preventive effective amount of a compound refers to an amount of a therapeutic agent, when used alone or in combination with other agents, that provides a preventive benefit in the process of preventing a disease, disorder or condition.
[0040] A third aspect of the present invention provides a pharmaceutical preparation for treating and / or preventing Charcot-Marie-Tooth disease.
[0041] Furthermore, the pharmaceutical preparation comprises the pharmaceutical composition described in the second aspect of the present invention.
[0042] Furthermore, the dosage form of the pharmaceutical preparation includes a dosage form for enteral administration or a dosage form for parenteral administration;
[0043] Optionally, the gastrointestinal dosage form includes solutions, granules, tablets, capsules, suspensions, powders, sustained-release agents, effervescent agents, emulsions, syrups, drops and / or chewable agents; optionally, the parenteral dosage form includes injection dosage forms, respiratory tract dosage forms, cavity dosage forms, mucosal dosage forms and / or skin dosage forms.
[0044] In some embodiments, the pharmaceutical composition or pharmaceutical preparation described in the present invention can be prepared into a dosage form suitable for oral administration, parenteral administration or topical administration by a known method, such as by conventional mixing, granulation, coating, solvent or freeze-drying methods, and the dosage form includes but is not limited to: tablets, capsules, granules, injections, powders for injection, transdermal patches, ointments, gels, suppositories, oral solutions, oral suspensions, emulsions for injection, oral emulsions, sustained-release tablets, controlled-release tablets, etc.
[0045] In some embodiments, the pharmaceutical composition or pharmaceutical preparation of the present invention may further comprise a pharmaceutically acceptable adjuvant, including but not limited to: a preservative, a solubilizer, a stabilizer, a wetting agent, an emulsifier, a sweetener, a colorant, a flavoring agent, a salt for regulating osmotic pressure, a buffer, a masking agent or an antioxidant. In addition, by comprising an ingredient that delays absorption, the pharmaceutical dosage form can be prolonged in absorption.
[0046] When using the pharmaceutical composition or pharmaceutical preparation provided by the present invention, its administration regimen and dosage regimen can be selected according to a variety of factors, including the type, species, age, weight, sex and type of disease to be treated by the subject; the severity of the disease to be treated; the route of administration; the patient's renal and liver function; and the specific compound or salt thereof used. An administration or dosage regimen can be used, for example, to prevent a disease, inhibit (completely or partially) a disease, or stop the development of the disease.
[0047] A fourth aspect of the present invention provides any of the following methods:
[0048] (1) A method for inhibiting axonal degeneration of MNs (motor neurons) after MORC2 mutation in vitro for non-therapeutic purposes, the method comprising administering an effective amount of the PAR hydrolase inhibitor described in the first aspect of the present invention to a cell system in need thereof;
[0049] (2) An in vitro non-therapeutic method for reducing DNA damage in MNs after MORC2 mutation, the method comprising administering an effective amount of the PAR hydrolase inhibitor described in the first aspect of the present invention to a cell system in need thereof.
[0050] Further, the MORC2 mutated MNs include MORC2 S87L -MNs, MORC2 Q400R -MNs and / or MORC2 D466N -MNs;
[0051] Optionally, reducing DNA damage in MNs after MORC2 mutation includes reducing the expression of DNA damage markers and / or increasing the expression of DNA repair proteins; optionally, the DNA damage markers include γH2AX; optionally, the DNA repair proteins include BRCA1, RAD51 and / or DNA-PKc.
[0052] In addition, the present invention also provides a method for treating and / or preventing Charcot-Marie-Tooth disease, the method comprising the following steps: administering a therapeutically and / or preventively effective amount of the PAR hydrolase inhibitor described in the first aspect of the present invention to a subject in need thereof.
[0053] In the present invention, the subject includes, but is not limited to, humans (i.e., males or females of any age group, e.g., pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., young adults, middle-aged adults, or older adults)) and / or non-human animals, e.g., mammals, e.g., primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and / or dogs. In some embodiments, the subject is a non-human animal. In some embodiments, the subject is a human.
[0054] The fifth aspect of the present invention provides the use of the PAR hydrolase inhibitor described in the first aspect of the present invention in the preparation of a drug for improving axonal degeneration and / or reducing DNA damage in Charcot-Marie-Tooth disease.
[0055] Compared with the prior art, the present invention has the following beneficial effects:
[0056] The present invention first discovered that PAR hydrolase inhibitors can significantly improve MORC2 S87L -MNs, MORC2 Q400R -MNs and MORC2 D466N -MNs' DNA damage and axonal degeneration have good potential for development into Charcot-Marie-Tooth disease therapeutic drugs, providing new ideas and strategies for the technical field of Charcot-Marie-Tooth disease therapeutic drug development, and have good clinical application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0057] Figure 1 :The induced differentiation process of iPSC-MNs, where A: In the iPSCs stage (induction differentiation day 0), the cells grow in sheets; B: In the NEPs stage (induction differentiation day 6), the cells are tightly clustered; C: In the MNPs stage (induction differentiation day 12), the cells are distributed in round clusters, and protrusions begin to appear around them; D: HB9 + In the MNs stage (18 days after differentiation), the cell clusters are irregularly round or oval, and more neurites begin to appear around them; E: CHAT + At the MNs stage (after the 24th day of induction of differentiation), several neurons gathered into a mass, and around the neuronal mass there were a large number of long axons with clear boundaries growing;
[0058] Figure 2 :MORC2 S87L -iPSCs, MORC2 Q400R -iPSCs, MORC2 D466N -Ki67 immunofluorescence detection of iPSCs, A: Control-iPSCs, MORC2 S87L -iPSCs, MORC2 Q400R-iPSCs, MORC2 D466N -Ki67 immunofluorescence image of iPSCs. Ki67-labeled cells are green, DAPI-labeled cell nuclei are blue, and Merge is a combination of the two channels of ki67 and DAPI; B: Statistical graph of fluorescence intensity of ki67 immunofluorescence (*p<0.05; **p<0.01);
[0059] Figure 3 :MORC2 S87L -iPSCs, MORC2 Q400R -iPSCs, MORC2 D466N -The percentage of ki67-positive cells in iPSCs, including A: Flow cytometry ki67 staining of the Control group and the MORC2 pathogenic variant group at the iPSC stage, marking the percentage of ki67-positive cells in the total number of cells in each group; B: Statistics of the percentage of ki67-positive cells by cell flow cytometry, the percentage of ki67-positive cells in the MORC2 pathogenic variant group decreased, and the difference in the S87L group was statistically significant (*p<0.05);
[0060] Figure 4 :MORC2 S87L -iPSCs, MORC2 Q400R -iPSCs, MORC2 D466N -iPSCs cell cycle detection, where A: iPSCs stage Control group and MORC2 pathogenic variant group, flow cytometry PI staining, distinguishing Control-iPSC, MORC2 S87L -iPSC, MORC2 Q400R -iPSC, MORC2 D466N -iPSC cell cycle distribution ratio in each group; B: Cell cycle ratio statistics of cell flow cytometry PI staining, the number of cells in the G1 phase of the S87L group increased significantly, and the difference was statistically significant (***p<0.001);
[0061] Figure 5 :MORC2 S87L 、MORC2 Q400R 、MORC2 D466N The results showed that the apoptosis of MNPs increased. A: In the MNPs stage, TUNEL was used to detect apoptotic cells, DAPI was used to stain the nucleus, and Tunel staining was used to mark apoptotic cells; B: In the MNPs stage, the ratio of apoptotic positive cells to total cells in each group was statistically analyzed. Compared with the normal control group, the MORC2 pathogenic variant group (MORC2 S87L 、MORC2 Q400R 、MORC2 D466N ) The percentage of apoptosis-positive cells increased significantly, scale bar 50 μm (****p<0.0001);
[0062] Figure 6 :MORC2 S87L 、MORC2 Q400R 、MORC2 D466N The results showed that the apoptosis of MNs increased, including A: TUNEL was used to detect apoptosis, DAPI was used to stain the nucleus, and Tunel staining was used to mark apoptotic cells at the MNs stage; B: Statistical analysis of the ratio of apoptotic positive cells to total cells in each group at the MNs stage. Compared with the normal control group, the MORC2 pathogenic variant group (MORC2 S87L 、MORC2 Q400R 、MORC2 D466N ) The percentage of apoptosis-positive cells increased significantly, scale bar 50 μm (****p<0.0001);
[0063] Figure 7 :MORC2 S87L 、MORC2 Q400R 、MORC2 D466N Leading to changes in the expression of apoptosis-related proteins in MNPs, including: A: In the MNPs stage, WB detected changes in the expression levels of apoptosis-related proteins; B: In the MNPs stage, compared with the Control group, the expression of Bax / BCL2 apoptosis-related proteins in the MORC2 pathogenic variant group increased; C: In the MNPs stage, compared with the Control group, the expression of Cleaved caspase-3 apoptosis protein in the MORC2 pathogenic variant group increased (*p<0.05; **p<0.01);
[0064] Figure 8 :MORC2 S87L 、MORC2 Q400R 、MORC2 D466N Leading to changes in the expression of MNs apoptosis-related proteins, including: A: In the MNs stage, WB detected changes in the expression levels of apoptosis-related proteins; B: In the MNs stage, compared with the Control group, the expression of Bax / BCL2 apoptosis-related proteins in the MORC2 pathogenic variant group increased; C: In the MNs stage, compared with the Control group, the expression of Cleaved caspase-3 apoptosis protein in the MORC2 pathogenic variant group increased (*p<0.05);
[0065] Fig. 9 :MORC2 S87L -MNs, MORC2 Q400R -MNs and MORC2 D466N -MNs morphology observed in HB9 + At the MNs stage, equal numbers of cells (5×10 4 ), induced to ChAT +At the MNs stage, compared with the Control group, under light microscopy, the density of motor neurons in the MORC2 pathogenic variant group was reduced and the axons were sparse, especially in the S87L group. Scale bar: 100μM;
[0066] Fig.10 :MORC2 S87L -MNs, MORC2 Q400R -MNs and MORC2 D466N -MNs neurite length analysis, where A: Neurons were labeled by immunofluorescence staining with the neuron-specific marker TUJ1, and neuronal morphology was observed under a fluorescence microscope. Compared with the Control group, the average length of motor neuron processes in the MORC2 pathogenic variant group was reduced; B: Analysis of the average length of neurites of neurons, using the imageJ software NeuronJ plug-in to analyze the neurite length of more than 50 neurons in each group, scale: 100 μM (***p < 0.001; ****p < 0.0001);
[0067] Fig.11 :MORC2 S87L -MNs, MORC2 Q400R -MNs and MORC2 D466N -MNs axon breakage ratio analysis, where A: Neurons were marked with immunofluorescence staining of neuron-specific marker TUJ1, and neuronal axon breakage was observed under a fluorescence microscope; B: Compared with the Control group, the motor neuron breakage ratio increased after MORC2 mutation, among which the S87L mutation had a more obvious effect; the imageJ software NeuronJ plug-in was used to analyze the axons of more than 50 neurons in each group. Scale bar: 100μM (*p<0.05; ****p<0.0001);
[0068] Fig.12 :MORC2 S87L -MNs, MORC2 Q400R -MNs and MORC2 D466N -MNs axonal varicose body analysis, where A: Neurons were labeled with immunofluorescence staining of neuron-specific marker TUJ1, and the axonal varicose bodies of neurons were observed under a fluorescence microscope; B: Compared with the Control group, the number of axonal varicose bodies per 100μM of motor neurons increased after MORC2 mutation, and the abnormal neuronal morphology ratio increased after MORC2 mutation, among which the S87L mutation had a more obvious effect; the imageJ software NeuronJ plug-in was used to analyze the axons of more than 50 neurons in each group. Scale bar: 100μM (**p<0.01; ****p<0.0001);
[0069] Fig.13 :MORC2S87L -MNPs, MORC2 Q400R -MNPs and MORC2 D466N -MNPs had no obvious DNA damage, among which, A: Neutral comet assay detected Control-MNPs, MORC2 S87L -MNPs, MORC2 Q400R -MNPs and MORC2 D466N -Single cell gel electrophoresis of each group of MNPs; B: Statistical graph of DNA percentage in comet tail, compared with Control-MNPs, MORC2 S87L -MNPs, MORC2 Q400R -MNPs and MORC2 D466N -There was no significant difference in the percentage of DNA in the tail of each group of MNPs, and DNA damage was not obvious;
[0070] Fig.14 :MORC2 S87L -MNPs, MORC2 Q400R -MNPs and MORC2 D466N -MNPs DNA damage marker γH2AX detection, where A: Control-MNPs, MORC2 S87L -MNPs, MORC2 Q400R -MNPs and MORC2 D466N -The expression of γH2AX protein and internal reference protein Actin in each group of MNPs; B: ImageJ was used to analyze the gray value of protein bands, and Actin was used as the internal reference to statistically analyze the relative expression level of proteins in each group;
[0071] Fig.15 :MORC2 S87L -MNPs, MORC2 Q400R -MNPs and MORC2 D466N - Downregulation of DNA damage repair proteins in MNPs qPCR was used to analyze the effect of MORC2 pathogenic variants on the mRNA expression of key repair proteins in the DNA repair pathway in the MNPs stage. A: The DNA-PKc transcription level in the MORC2 pathogenic variant group was significantly downregulated, and there was no significant difference in the 53BP1 transcription level; B: The BRCA1 and RAD51 transcription levels in the MORC2 pathogenic variant group were significantly decreased; C: The MORC2 transcription level in the MORC2 pathogenic variant group showed a downward trend; D: MORC2 S87L -XPD transcription levels increased in MNPs, and OGG1 transcription levels showed a decreasing trend in the MORC2 pathogenic variant group (*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001);
[0072] Fig.16 :MORC2 S87L -MNs, MORC2 Q400R -MNs and MORC2 D466N -MNs showed obvious DNA damage, among which A: Neutral comet assay to detect single cell gel electrophoresis of each group at the MN stage; B: The tail DNA percentage, comet tail length, and comet tail moment of the MORC2 pathogenic variant group were significantly increased (**p<0.01; ****p<0.0001);
[0073] Fig.17 :MORC2 S87L -MNs, MORC2 Q400R -MNs and MORC2 D466N -MNs DNA damage marker γH2AX detection, where A: Control-MNs, MORC2 S87L -MNs, MORC2 Q400R -MNs and MORC2 D466N -The expression of γH2AX protein and internal reference protein Actin in each group of MNs; B: ImageJ was used to analyze the gray value of protein bands, and Actin was used as the internal reference to statistically analyze the relative expression levels of proteins in each group (*p<0.05; **p<0.01);
[0074] Fig.18 :MORC2 S87L -MNs, MORC2 Q400R -MNs and MORC2 D466N -MNs DNA repair proteins were downregulated, and qPCR was used to analyze the effect of MORC2 pathogenic variants on the mRNA expression of key repair proteins in the DNA repair pathway in the MNs stage. Among them, A: The DNA-PKc transcription level of the MORC2 pathogenic variant group was significantly downregulated, and the 53BP1 transcription level showed an increasing trend, among which MORC2 S87L -MNs were more significant; B: BRCA1 and RAD51 transcription levels were significantly decreased in the MORC2 pathogenic variant group; C: PARP1 transcription level showed a downward trend in the MORC2 pathogenic variant group, among which MORC2 S87L -MNs decreased significantly; D: XPD transcription level in MORC2 pathogenic variant group showed a downward trend, OGG1 transcription level showed an increasing trend, MORC2 Q400R -MNs were more significant (*p<0.05; **p<0.01; ****p<0.01);
[0075] Fig.19: DNA damage increased in the MORC2 mutant group at the MNPs stage after MMS-induced DNA damage stress, where A: At the MNPs stage, cells were incubated with 200 μM MMS for 36 hours, and then whole-cell proteins were collected to detect the expression level of γH2AX using WB; B: ImageJ was used to analyze the grayscale value of protein bands, and the relative expression of γH2AX protein and internal reference Actin in the negative control group (MMS-) without MMS was statistically represented; C: The relative expression of γH2AX protein and internal reference Actin in the experimental group (MMS+) treated with 200 μM MMS (*p<0.05; **p<0.01);
[0076] Fig. 20 :MORC2 S87L -MNs, MORC2 Q400R -MNs and MORC2 D466N -MORC2 and PARP1 protein changes in MNs, where A: Immunoblotting was used to detect MORC2, PARP1, and Actin protein levels in each group of MNs; B: Compared with the Control group, the MORC2 protein expression in the MORC2 pathogenic variant group was downregulated, and MORC2 S87L and MORC2 D466N More significant; C: Compared with the Control group, the expression of PARP1 protein in the MORC2 pathogenic variant group was significantly downregulated (*p<0.05; **p<0.01);
[0077] Fig.21 :MORC2 S87L -MNs, MORC2 Q400R -MNs and MORC2 D466N -PAR protein changes in MNs, where A: Western blotting was used to detect the levels of PAR and Actin proteins in each group of MNs; B: Compared with the Control group, the expression of PAR protein in the MORC2 pathogenic variant group was significantly downregulated (*p<0.05);
[0078] Fig. 22 :MORC2 S87L -MNs, MORC2 Q400R -MNs and MORC2 D466N -TUJ1 protein changes in MNs, where A: Immunoblotting was used to detect the levels of TUJ1 and Actin proteins in each group of MNs; B: Compared with the Control group, the expression of TUJ1 protein in the MORC2 pathogenic variant group was significantly downregulated (*p<0.05);
[0079] Fig.23 : MORC2 expression after MMS-induced DNA damage stress S87L-MNPs, MORC2 Q400R -MNPs and MORC2 D466N -MNPs reduced PAR, where A: In the MNP stage, 200 μM MMS was used to incubate cells for 36 hours, and then the whole cell protein was collected to detect the expression level of PAR, the activated form of PARP1; B: ImageJ was used to analyze the gray value of protein bands, and the statistics showed the relative expression of PAR protein and internal reference Actin in the negative control group (MMS-) without MMS; C: In the experimental group treated with 200 μM MMS (MMS+), compared with Control-MNPs, MORC2 S87L -MNPs, MORC2 Q400R -MNPs and MORC2 D466N -The expression of PAR protein in MNPs was significantly decreased (*p<0.05; **p<0.01);
[0080] Fig.24 :Changes in MORC2 and PARP1 in motor neurons after MORC2 mutation. Plasmids carrying MORC2 wild type (WT), S87L, Q400R, and 466N were transfected into 293T cells. After 36 hours of transfection, whole-cell proteins were extracted for immunoprecipitation. Compared with MORC2 wild type, the PARP1 protein interacting with MORC2 mutant protein was significantly reduced.
[0081] Fig.25 : Changes in cell viability caused by small molecules at different concentrations, where A: After incubation of PDD small molecules at different concentrations for 48 hours, the CCK8 method was used to detect changes in cell viability, and it was preliminarily confirmed that the appropriate working concentration of PDD was 0.5 μM; B: After incubation of NMN small molecules at different concentrations for 48 hours, the CCK8 method was used to detect changes in cell viability, and it was preliminarily confirmed that the appropriate working concentration of NMN was 500 μM;
[0082] Fig.26 :PDD improves MORC2 S87L -MNs, MORC2 Q400R -MNs and MORC2 D466N -MNs morphology, where A: At the 18D stage, after being treated with PDD (0.5 μM) for 1 week, neurons were specifically labeled with TUJ-1 at 24D to evaluate the morphological changes of neurons in each group; B: Statistical analysis of MNs neurite length after PDD treatment; C: Statistical analysis of MNs neurite branch number after PDD treatment (*p<0.05; **p<0.01; ***p<0.001);
[0083] Fig. 27 :NMN on MORC2 S87L-MNs, MORC2 Q400R -MNs and MORC2 D466N -The morphological effects of MNs, where A: At the 18D stage, after being treated with NMN 500μM for 1 week, neurons were specifically labeled with TUJ-1 at 24D to evaluate the morphological changes of neurons in each group; B: Statistical analysis of the length of MN neurites after NMN treatment; C: Statistical analysis of the number of MN neurite branches after MN treatment (*p<0.05; ****p<0.0001);
[0084] Fig.28 :PDD adds MORC2 S87L -PAR expression in MNs, improving DNA damage, where A: After 1 week of treatment with PDD (0.5 μM), whole cell protein was extracted, and WB was used to detect the healthy control group and MORC2 S87L -MNs, MORC2 Q400R -MNs, MORC2 D466N -MNs expression of PAR and γH2AX proteins in each group; B: WB gray value analysis of PAR protein in each group; C: WB gray value analysis of γH2AX protein in each group. DETAILED DESCRIPTION
[0085] The present invention is further described below in conjunction with specific embodiments, which are only used to explain the present invention and cannot be understood as limiting the present invention. It can be understood by those skilled in the art that various changes, modifications, substitutions and variations can be made to these embodiments without departing from the principles and purpose of the present invention, and the scope of the present invention is defined by the claims and their equivalents.
[0086] The materials used in the present invention are easily obtained by ordinary technicians in the field and can be obtained from commercial channels unless otherwise specified. The experimental methods in the present invention that do not specify specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer. In particular, the following examples are only used to illustrate the present invention and should not limit the scope of the present invention in any way.
[0087] Example 1MORC2 S87L -iPSC-MNs, MORC2 Q400R -iPSC-MNs and MORC2 D466N -Observation of cell viability and neuronal morphology of iPSC-MNs
[0088] 1.1 Experimental Materials
[0089] In the previous research, the inventor team established iPSCs derived from urine cells of three CMT2Z patients carrying MORC2 gene p.S87L, p.Q400R and p.D466N mutations and one healthy control (abbreviated as: MORC2 S87L -iPSCs, MORC2 Q400R -iPSCs, MORC2 D466N -iPSCs, Control-iPSCs), it was verified that these iPSCs all had normal karyotype, MORC2 gene mutation sites that were completely consistent with the donor, high expression of SSEA4, OCT4, NANOG and TRA-1-60 stem cell markers, and the ability to differentiate into the inner, middle and outer germ layers, and no exogenous plasmids were integrated into the genome of these iPSCs during the induction process (ZENG S, YANG H, WANG B, et al. The MORC2 p.S87L mutation reduces proliferation of pluripotent stem cells derived from a patient with the spinal muscular atrophy-like phenotype by inhibiting proliferation-related signaling pathways [J]. Neural Regeneration Research, 2024, 19 (1): 205-211.). In the preliminary experiments, our team has been able to maturely differentiate iPSCs from three CMT2Z patients and one healthy control into medullary anterior horn motor neurons (ChAT + The iPSCs-derived motor neurons (MNs) have been identified and markers for each differentiation stage have been identified. These iPSCs-derived motor neurons (MNs) have a genetic background that is completely consistent with that of CMT2Z patients, and can more accurately reveal the molecular mechanism of MORC2 gene mutations, which will help screen and develop safer and more effective treatments.
[0090] In a previous study, MORC2 from three CMT2Z patients was S87L -iPSC-MNs, MORC2 Q400R -iPSC-MNs, MORC2 D466N The morphology, function and transcriptome of iPSC-iPSC-MNs and control-iPSC-MNs from a healthy control were analyzed. In the process, it was found that compared with the control, MORC2 S87LThe group showed proliferation disorder, MORC2 S87L 、MORC2 Q400R and MORC2 D466N MNs show morphological abnormalities and DNA damage phenotypes, MORC2 S87L 、MORC2 Q400R and MORC2 D466N Transcriptome analysis of MNPs revealed that abnormalities in the PI3K-AKT and MAPK / ERK pathways were the main drivers of MORC2 S87L The potential mechanism affecting proliferation: ASO targeted intervention of the MORC2 gene p.S87L mutation at the iPSCs stage can activate the PI3K-AKT and MAPK / ERK pathways and rescue the proliferation disorder phenotype (ZENGS, YANG H, WANG B, et al. The MORC2p.S87L mutation reduces proliferation of pluripotent stem cells derived from a patient with the spinal muscularatrophy-like phenotype by inhibiting proliferation-related signaling pathways[J]. Neural Regeneration Research, 2024, 19(1): 205-211.).
[0091] 1.2 Culture and passaging of iPSCs
[0092] 1.2.1 Culture of iPSCs
[0093] This experiment used iPSCs derived from human urine-derived somatic cells. This cell line was obtained by our research group from the patient's urine. During the culture process, iPSCs were maintained in a medium containing mTeSR1 and the culture plates were coated with Matrigel matrix gel. The culture conditions were 37°C and 5% CO. 2 and a relative humidity of 95% in a cell culture incubator.
[0094] 1.2.2 Passaging of iPSCs
[0095] Under a sterile operating table, an inverted microscope was used to observe the cell status of the iPSCs culture plate. When the cell confluence reached 70-80%, conventional methods were used for subculturing.
[0096] 1.3 iPSCs directed differentiation into MNs
[0097] The above four groups of iPSCs were transformed into neuroepithelial progenitors (NEPs), motor neuron progenitors (MNPs), postmitotic motor neurons (HB9 positive motor neurons, HB9) and mitotic progenitors (PNPs). + MNs) stage, they were induced to differentiate into spinal cord anterior horn motor neurons (ChAT positive motor neurons, ChAT + MNs), hereinafter referred to as: Control-MNs, MORC2 S87L -MNs, MORC2 Q400R -MNs, MORC2 D466N-MNs. (1) Prepare a basal chemical culture medium consisting of 24 mL DMEM / F12 medium, 24 mL Neurobasal medium, 0.25 mL N2, 0.5 mL B27, 17 μL Ascorbic acid, and 0.5 mL Glutamax. (2) On the day before subculturing, soak a 6-well plate with 1 mL of Matrigel working solution per well and incubate overnight in a 37°C cell culture incubator. On the first day of induction, replace the iPSCs-specific mTeSR1 medium with A chemically defined medium (basal chemically defined medium supplemented with 15 μL 10 mM CHIR99021, 4 μL 25 mM DMH-1, and 4 μL 25 mM SB431542), and change the medium every 2 days. (3) On day 6, iPSCs had differentiated into neuroepithelial progenitor cells (NEPs). NEPs were digested with 1 mg / mL Dispase (50 mg Dispase powder dissolved in 50 mL PBS), then passaged 1:6 and continued to be cultured in B chemically defined medium (basal chemically defined medium with 0.2 μL 25 mM Retinoic acid, 5 μL 5 mM Purmorphamine, 5 μL 10 mM CHIR99021, 4 μL 25 mM DMH-1, and 4 μL 25 mM SB431542). The medium was changed every 2 days. (4) On day 12, NEPs were further differentiated into neuronal progenitor cells (MNPs). At this time, the medium was replaced with C chemical defined medium (basal chemical defined medium with 0.2 μL 25 mM Retinoic acid, 5 μL 5 mM Purmorphamine, 15 μL 10 mM CHIR99021, 4 μL 25 mM DMH-1, 4 μL 25 mM SB431542 and 25 μL 1000 mM Valproic acid). The medium was replaced every 2 days to culture the MNPs. (5) MNPs were maintained in C chemical defined medium, subcultured once a week, digested with 1 mg / mL Dispase, and subcultured at a ratio of 1:6. (6) C chemical defined medium and DMSO were used to prepare a freezing solution at a ratio of 9:1 (for example, preparation method: 90 mL C chemical defined medium and 10 mL DMSO were mixed) and the MNPs cells were frozen. When thawing, refer to the thawing process of iPSCs culture. (7) On day 12+0, the MNPs cells were digested with Dispase (1 mg / mL) and then cultured in D chemically defined medium (basal chemically defined medium supplemented with 1 μL 25 mM Retinoic acid and 1 μL 5 mM Purmorphamine). The medium was changed every 2 days.(8) On day 12+6, MNPs differentiated into postmitotic motor neurons (HB9. + MNs). HB9 was digested with Accumax enzyme + MNs were grown into single cells and plated on Matrigel-coated culture plates. The culture medium was replaced with E chemically defined medium (basal chemically defined medium with 1 μL 25 mM Retinoic acid, 1 μL 5 mM Purmorphamine, and 2 μL 2.5 mM Compound E). The culture medium was replaced every 2 days. After one week of culture, the cells differentiated into spinal anterior horn motor neurons (ChAT + MNs), the culture medium can be maintained in E chemically defined medium, with the medium changed every 2 days. (9) During differentiation induction, in order to ensure the correctness of the induction, the cell markers of motor neuron precursor cells (MNPs) stage, oligodendrocyte lineage transcription factor 2 (OLIG2), postmitotic motor neurons (HB9 + MNs) cell markers Homeobox HB9 (HB9) and spinal cord anterior horn motor neurons (ChAT) + MNs) should be identified by cell-mediated immunohistochemistry.
[0098] 1.4 Cell immunofluorescence
[0099] 1.4.1 Cell plating
[0100] The cells were cultured at 37°C and 5% CO 2 The cells were cultured under the conditions of 4% paraformaldehyde and 1% paraformaldehyde to a confluence suitable for the experimental requirements, and the medium was changed every 2 days during the culture process.
[0101] 1.4.2 Immunofluorescence
[0102] (1) Gently wash the cells in the 24-well plate with PBS three times to remove the culture medium and non-adherent cells. Fix the cells with 300 μL of 4% paraformaldehyde solution for 10 minutes. (2) Place the fixed cell slide on the sealing film on the dish for easy removal later. Gently wash the fixed cells with PBS three times. Add 200 μL of 0.03% Triton X-100 from the edge of the slide and permeabilize for 10 minutes at room temperature. Gently wash with PBS three times. (3) Use 3% BSA as blocking solution and block for 30 minutes at room temperature. (4) Cover the cells with primary antibody dilution and incubate overnight at 4°C. It is best to place them in a sealing dish and place toilet paper soaked with deionized water around them to prevent the primary antibody from evaporating overnight. (5) Wash the cells with PBS three times, 5 minutes each time. Cover the cells with fluorescently labeled secondary antibody dilution and incubate at room temperature in the dark for 2 hours. (6) Wash the cells with PBS three times, 5 minutes each time. Cover the cells with DAPI solution (diluted to 1 μg / mL) and incubate at room temperature in the dark for 1-2 minutes. (7) Wash the cells 3 times with PBS, 5 minutes each time. Place the slide upside down on a glass slide to which an appropriate amount of fluorescent antifade agent has been added. Operate slowly to avoid bubbles. After the antifade agent dries, apply colorless nail polish around it to seal it to prevent air from entering or oxidation. After completion, store at 4°C in the dark.
[0103] 1.5 Flow cytometry
[0104] (1) Wash the cells to be tested with PBS, digest them with 0.05% trypsin, discard the trypsin after 4 minutes, and add culture medium to resuspend the cells. (2) Centrifuge the cell suspension at 1000rpm for 5 minutes, discard the supernatant, wash the cells once with PBS, centrifuge again at 1000rpm for 5 minutes, and discard the supernatant. (3) Resuspend the cells in 500μL of 70% anhydrous ethanol prepared with pre-cooled PBS in each tube, slowly add, and gently blow until there are no cell clumps to form a single cell suspension. Then place it in a refrigerator at -20℃ and fix it for 1 hour. (4) Centrifuge at 1000rpm for 5 minutes, discard the supernatant, wash the cells twice with PBS solution containing 1% BSA, centrifuge at 1000rpm for 5 minutes after each wash, and discard the supernatant. (5) Resuspend the cells in 100 μL flow cytometry antibody incubation solution (0.1 g BSA, 10 mL PBS and 50 μL Tween-20) with an appropriate amount of antibody (used according to the instructions, generally 1 μL), and incubate at room temperature for 1 hour. (6) After centrifugation at 1000 rpm for 5 minutes, recover the primary antibody, add PBS solution containing 1% BSA to wash the cells once, transfer to a flow cytometer and pass through a sieve to make the cells single cells. (7) Detect the percentage of cell staining on a flow cytometer, use the blank group as a negative control, and use Flowjo7.6 software to analyze the data and plot the graph. Analyze the data of more than 3 independent experiments for each group.
[0105] 1.6 TUNEL staining
[0106] (1) Fix the cells with 4% paraformaldehyde solution at room temperature for 30 minutes. (2) Wash the fixed samples with PBS 3 times, 5 minutes each time. (3) Treat the samples with PBS solution containing 0.1% Triton X-100 and incubate at room temperature for 10 minutes to increase the permeability of the TUNEL reaction mixture. (4) Set up a positive control group (Positive group, using 200U / mL DNase I, incubated at 37℃ for 30min to cause DNA breakage) and a negative control group (Negative group, incubated with PBS at 37℃ for 30min). (5) Fluorescent labeling: According to the instructions of the kit, for the Positive group and the experimental group, prepare the TUNEL reaction mixture (5 μL TdT enzyme, 10 μL fluorescent marker and 35 μL TdT equilibration buffer, a total of 50 μL TUNEL detection solution), then add it to the sample and incubate it at 37°C in the dark for 1 hour; for the Negative group, prepare the TUNEL reaction mixture (0 μL TdT enzyme, 10 μL fluorescent marker and 40 μL TdT equilibration buffer, a total of 50 μL TUNEL detection solution), then add it to the sample and incubate it at 37°C in the dark for 1 hour. (6) Wash with PBS three times, 5 minutes each time. (7) Incubate with DAPI stain at room temperature for 5 minutes. (8) Seal the slides with antifade fluorescent mounting medium and seal the edges with colorless nail polish, store at 4°C, and take images under a fluorescence microscope as soon as possible. (9) Analyze the ratio of apoptotic cells to total cells in more than 10 fields of view in each group.
[0107] 1.7 Western Blot
[0108] Extraction of total cell protein, BCA quantification, preparation of protein samples, protein electrophoresis, membrane transfer, incubation, development, and protein quantitative analysis (each group analyzed more than 3 independent experimental data).
[0109] 1.8 Observation of neuronal morphology
[0110] (1) Inducing differentiation of 18D HB9 + MNs, cells were washed twice with PBS and digested with Accumax enzyme at 37°C for 3 minutes; after cell clumps were removed, cells were resuspended in E chemically defined medium containing 10 μM Y27632. (2) The cell suspension was filtered through a 70 μm cell filter to remove residual large cell clumps. (3) After cell counting, an equal number of cells (5×10 4 ) into 6-well plates, (1×10 4 ) were placed in a 24-well plate with a cell slide and cultured for 1 week to differentiate into ChAT +(4) Observe the growth status of neurons under a light microscope or use immunofluorescence staining of the neuron-specific marker TUJ1 to observe the morphological changes of axons.
[0111] 1.9 Statistical analysis
[0112] This study used Graphpad Prism9.0 software as the main data statistics and analysis tool. When describing the quantitative data, the mean (Mean) ± standard deviation (SD) method was used to present the central tendency and discreteness of the data. For the comparison of three or more groups of data, this study used one-way ANOVA for in-depth comparative analysis to explore whether there were statistically significant differences between the groups. For comparison scenarios with only two groups of data, this study used the t-test between the two groups as the analysis method. In all the above statistical tests, a p value less than 0.05 was used as the threshold for judging whether the difference was statistically significant.
[0113] 1.10 Experimental Results
[0114] 1.10.1 iPSC-MNs differentiation process
[0115] The induction and differentiation process of iPSCs-MNs is as follows Figure 1 As shown. iPSCs were seeded on well plates pre-coated with Matrigel matrix gel, using serum-free basal chemically defined medium. By adding different signaling pathway regulating small molecules, the cells were differentiated from the iPSCs stage (differentiation induction day 0) ( Figure 1 A), in which the cells are in a dense clone state and gradually induced to the NEPs stage (6th day of differentiation induction). In the NEPs stage, the cells grow in clusters and are nearly round or elliptical in shape ( Figure 1 B) Subsequently, the cells were gradually induced to the MNPs stage (12th day of differentiation induction). In the MNPs stage, some protrusions began to appear around the cell clusters ( Figure 1 C) Then, the cells were further induced to HB9 + MNs stage (18th day of differentiation induction), at this stage, a large number of nerve axons appeared around the cell clusters ( Figure 1 D) Finally, the cells are induced to differentiate into ChAT + MNs stage (24 days after differentiation induction), at this stage, the cell bodies of neurons are enlarged, the growth of axons is more obvious and the number of branches increases, and the processes between neurons are interconnected to form a complex neural network structure ( Figure 1 E). This series of processes marks the completion of the induced differentiation process from iPSCs to mature motor neurons ( Figure 1 AE).
[0116] 1.10.2MORC2 S87L -iPSCs show proliferation disorder
[0117] Ki67 was used as a proliferation marker to detect the proliferation of Control-iPSCs and MORC2 cells by cell immunofluorescence technique. S87L -iPSCs, MORC2 Q400R -iPSCs, MORC2 D466N The ki67 fluorescence intensity in MORC2-iPSCs can reflect the neuronal proliferation. S87L -The average fluorescence intensity of Ki67 in iPSCs was significantly reduced (see Figure 2 A), reduced to about half of the control group (see Figure 2 B), indicating that MORC2 S87L Inhibit iPSCs proliferation.
[0118] To further verify this phenomenon, we used Ki67 staining flow cytometry to detect the proportion of Ki67-positive cells in each group of cells. The results showed that compared with Control-iPSCs, MORC2 S87L -The proportion of Ki67-positive cells in iPSCs decreased significantly (see Figure 3 A), MORC2 Q400R -iPSCs and MORC2 D466N -The proportion of Ki67-positive cells in iPSCs showed a downward trend, but did not reach a significant difference (see Figure 3 B). The results of flow cytometry were consistent with those of immunofluorescence, indicating that MORC2 pathogenic variants can lead to proliferation blockage of iPSCs, and the proliferation blockage caused by the S87L variant site is more significant.
[0119] Propidium iodide (PI) staining was further used to analyze the cell cycle distribution. The results showed that compared with Control-iPSCs, MORC2 S87L -iPSCs have a significantly increased proportion of the G0 / G1 phase of the cell cycle, MORC2 Q400R -iPSCs and MORC2 D466N -The proportion of G0 / G1 phase in the cell cycle of iPSCs did not change significantly, suggesting that MORC2 S87L Can cause cell cycle G0 / G1 phase arrest (see Figure 4 A, B).
[0120] 1.10.3MORC2 S87L -iPSCs, MORC2 Q400R -iPSCs and MORC2 D466N- Increased apoptosis in MNPs and MNs stages of iPSC differentiation
[0121] TUNEL staining was used to detect the percentage of apoptotic cells. By comparing with the Control group, it was found that the MNPs stage ( Figure 5 A, B) and MNs stage ( Figure 6 A, B), MORC2 S87L 、MORC2 Q400R 、MORC2 D466N The percentage of apoptotic cells in the two groups increased significantly. Compared with the MNPs stage, MORC2 S87L 、MORC2 Q400R 、MORC2 D466N The apoptotic cell percentage was higher in the group.
[0122] The ratio of apoptosis protein Bax to apoptosis protective protein BCL2 (Bax / Bcl2) can also reflect the situation of cell apoptosis. The larger the Bax / Bcl2 ratio, the higher the level of apoptosis. Figure 7 A, B) and MNs stage ( Figure 8 A, B), compared with the Control group, MORC2 S87L 、MORC2 Q400R 、MORC2 D466N The Bax / Bcl2 ratio increased in the group, and MORC2 S87L 、MORC2 D466N The group increased significantly, MORC2 Q400R The Bax / Bcl2 ratio in the two groups also showed an increasing trend, but there was no statistical difference.
[0123] WB was used to detect the expression of apoptosis marker protein Cleaved Caspse-3. Compared with the Control group, MORC2 Q400R and MORC2 D466N The expression of Cleaved Caspse-3 in the two groups was statistically significant. S87L The expression of Cleaved Caspse-3 in the two groups showed an increasing trend, but there was no statistical difference ( Figure 7 A, B); at the MNs stage, MORC2 S87L 、MORC2 Q400R 、MORC2 D466N The expression of Cleaved Caspse-3 in all groups increased, and MORC2 D466N The expression of CleavedCaspse-3 in the two groups increased significantly ( Figure 8 A, B). The above results suggest that MORC2 S87L-iPSCs, MORC2 Q400 -iPSCs and MORC2 D466N - Increased cell apoptosis at the MNPs and MNs stages of iPSCs differentiation.
[0124] 1.10.4MORC2 S87L -MNs, MORC2 Q400R -MNs and MORC2 D466N -MNs morphological changes
[0125] Neuronal axonal degeneration is a characteristic change of CMT2. To further observe the effect of MORC2 pathogenic variants on the morphology of motor neurons, the growth status of motor neurons was observed under a light microscope. S87L 、MORC2 Q400R 、MORC2 D466N The growth density of motor neurons in the group was reduced, the axons became shorter, the neural network formed was sparser, and the confluence of cells under light microscopy was significantly reduced, especially MORC2 S87L The most serious group ( Fig. 9 ).
[0126] The neuron-specific marker TUJ1 was used to label motor neurons, observe neuron morphology, and quantify the average length of neurites, axonal breakage ratio, and number of varicose bodies. The results showed that compared with the control group, the MORC2 pathogenic variant group (MORC2 S87L 、MORC2 Q400R and MORC2 D466N )'s average neurite length was significantly shortened ( Fig.10 A, B), the axonal breakage ratio of neurons increased significantly ( Fig.11 A, B), the number of axonal varicose bodies increased significantly per 100 μM ( Fig.12 A, B), MORC2 S87L The above results suggest that MORC2 S87L 、MORC2 Q400R 、MORC2 D466N Can lead to abnormal morphology of MNs.
[0127] Example 2MORC2 S87L -iPSC-MNs, MORC2 Q400R -iPSC-MNs and MORC2 D466N DNA damage analysis of iPSC-MNs 2.1 Neutral comet assay
[0128] (1) Cut the tin foil into long strips and stick them on the edge of the slide, and fix them with different colored thin wires to distinguish different samples and reduce degumming during the experiment. (2) Preheat the slide, quickly absorb 150 μL of 0.75% normal melting point agarose solution (0.0375g normal melting point agarose powder, dissolved in 5mL PBS solution), evenly spread it in the electrophoresis tank, and place it at 4℃ for 5 minutes to solidify. (3) Take 80 μL of 1% low melting point agarose solution (0.05g low melting point agarose powder, dissolved in 5mL PBS solution, kept at 37℃) and 20 μL of the cell suspension to be tested (concentration of about 1×10 5 cells / mL), and then quickly spread it on the first layer of gel and place it at 4°C for 5 minutes to solidify. (4) Quickly draw 100 μL of 1% low melting point agarose solution (keep warm at 37°C), spread it on the second layer of gel and place it at 4°C for 5 minutes to solidify. (5) Place the prepared slide in a lysis box and add an appropriate amount of freshly prepared neutral lysis solution (5.844 g NaCl powder, 0.559 g EDTA-Na 2 .2H 2 O powder, 0.061g Tris powder, dissolved in 40mL double distilled water and added 5mL DMSO and 0.5mL Triton X-100 (100%)), lysed at 4℃ in the dark for 1.5 hours. (6) Place the washed slide in a despinning box, add an appropriate amount of 4℃ pre-cooled 1×TBE solution (50mL 10×TBE solution, diluted in 450mL double distilled water), and despin for 40 minutes. (7) Place the despinned slide in an electrophoresis tank and add an appropriate amount of electrophoresis buffer. Set the electrophoresis condition to 20V constant voltage electrophoresis for 25 minutes. (8) Wash off the electrophoresis solution on the surface of the slide, add 60μL nucleic acid dye solution (10μL nucleic acid dye solution diluted in 10mL deionized water), stain for 30 minutes in the dark, observe and take pictures under a fluorescence microscope. (9) CASP comet analysis software was used to process the captured cell comet images. The percentage of DNA intail and tail moment were used as quantitative indicators to reflect the degree of cell DNA damage. 50 cells were randomly analyzed in each experimental group, and the experiment was repeated 3 times.
[0129] 2.2 Real-time fluorescence quantitative PCR
[0130] Conventional methods were used for RNA extraction and quality control, RT-PCR, and qPCR.
[0131] 2.3 Western blotting
[0132] As described in Example 1.
[0133] 2.4 Statistical analysis
[0134] As described in Example 1.
[0135] 2.5 Experimental Results
[0136] 2.5.1MORC2 S87L -MNPs, MORC2 Q400R -MNPs and MORC2 D466N -MNPs show downregulation of DNA repair proteins
[0137] Neutral comet assay, i.e. single cell gel electrophoresis assay, was used to detect the extent of double-strand DNA breaks in cells. The tail moment of the comet, the percentage of DNA in the tail, etc. were used to quantify the severity of DNA damage in each group of cells. The results showed that compared with the Control-MNPs group, MORC2 S87L -MNPs, MORC2 Q400R -MNPs and MORC2 D466N -MNPs group had no significant increase in the percentage of DNA in the comet tail, indicating no obvious DNA damage ( Fig.13 A, B). WB was used to detect the expression level of DNA damage marker γH2AX protein. Compared with the Control-MNPs group, MORC2 S87L -MNPs, MORC2 Q400R -MNPs and MORC2 D466N -MNPs group had no significant increase in γH2AX protein expression, indicating that DNA damage was not significant ( Fig.14 A, B).
[0138] qPCR was used to detect the transcriptional levels of key repair proteins in the DNA repair pathway. The results showed that compared with the Control-MNPs group, MORC2 S87L -MNPs, MORC2 Q400R -MNPs and MORC2 D466N -The transcription levels of BRCA1 and RAD51, key proteins of the HR pathway, decreased significantly in the MNPs group; DNA-Pkc, a key protein of the NHEJ pathway, decreased significantly in MORC2 Q400R -MNPs and MORC2 D466N -MNPs group significantly decreased in MORC2 S87L -MNPs group showed a decreasing trend but no statistical difference; 53BP1, a key protein in the non-homologous end joining repair pathway, was expressed in MORC2 S87L -MNPs, MORC2 Q400R -MNPs and MORC2 D466N -MNPs group showed no significant changes. Fig.15 AD). 2.5.2MORC2 S87L -MNs, MORC2Q400R -MNs and MORC2 D466N -MNs show DNA damage and downregulation of DNA repair proteins
[0139] In the neutral comet assay, MORC2 S87L -MNs, MORC2 Q400R -MNs and MORC2 D466N The comet tail length, tail moment and tail DNA percentage of the -MNs group were significantly increased, indicating that DNA damage increased in each MORC2 pathogenic variant group at the MNs stage ( Fig.16 A, B). Western blotting was used to detect the marker protein γH2AX in the DNA damage repair process. It was found that compared with the Control-MNs group, MORC2 S87L -MNs, MORC2 Q400R -MNs and MORC2 D466N The expression level of γH2AX protein in the -MNs group was significantly increased, which was consistent with the results of the comet assay, suggesting that MORC2 S87L -MNs, MORC2 Q400R -MNs and MORC2 D466N -MNs have significant DNA damage ( Fig.17 A, B).
[0140] qPCR was used to detect the transcription levels of key repair proteins in the DNA repair pathway in each group of MNs. The results showed that compared with Control-MNs, MORC2 S87L -MNs, MORC2 Q400R -MNs and MORC2 D466N The transcription levels of DNA-Pkc, a key repair protein of the NHEJ pathway, and BRCA1 and RAD51, a key repair protein of the HR pathway, decreased significantly in MORC2-MNs, and the transcription level of PARP1, a DNA damage response effector protein, increased significantly. S87L -MNs, MORC2 Q400R -MNs and MORC2 D466N -MNs showed a down-regulation trend, with MORC2 being the most S87L -MNs were the most significant. Unlike other repair proteins, 53BP1, a key repair protein in the NHEJ pathway, and γH2AX are considered markers of DNA breaks, and their expression is proportional to the level of DNA damage. S87L -MNs, MORC2 Q400R -MNs and MORC2 D466N The transcription level of 53BP1 in MNs showed an increasing trend, with MORC2 being the mostS87L -MNs showed the most significant difference, suggesting increased DNA damage in the MORC2 pathogenic variant group. Fig.18 AD).
[0141] 2.5.3 MORC2 after MMS-induced DNA damage S87L -MNPs, MORC2 Q400R -MNPs and MORC2 D466N -MNPs showed significant DNA damage
[0142] In previous studies, we found that there was no obvious DNA damage in the MNPs stage, but there was an obvious downregulation of the expression spectrum of DNA repair proteins. With the development of neurons, the DNA damage phenotype gradually became significant in the MNs stage. We speculate that the DNA repair ability decreases in the early stage of neuronal development (MNPs stage). At this time, there is less stress, the DNA damage is mild, and DNA damage and repair can still reach a balance. However, as the developmental stress of neurons gradually increases, the DNA repair ability is insufficient to repair the damaged DNA, and DNA damage gradually accumulates (MNs stage). To verify this hypothesis, we used methyl methanesulfonate (MMS) to induce DNA double-strand breaks in the MNPs stage when DNA damage is not yet obvious. After 36 hours of treatment, WB was used to detect the level of DNA damage marker γH2AX. The results showed that compared with Control-MNPs, MORC2 S87L -MNPs, MORC2 Q400R -MNPs and MORC2 D466N -MNPs significantly increased γH2AX ( Fig.19 ).
[0143] The above results suggest that in the early stage of neuronal development, pathogenic variants of MORC2 can cause down-regulation of the expression of DNA repair proteins, but at this time there is less stress, DNA damage and repair are still balanced, and no obvious DNA damage occurs; as neurons develop and mature, stress increases, and the DNA repair pathway cannot completely repair damaged DNA, resulting in accumulation of DNA damage, which may be one of the main mechanisms by which pathogenic variants of MORC2 lead to neuronal apoptosis.
[0144] Example 3MORC2 S87L 、MORC2 Q400R and MORC2 D466N Exploration of molecular mechanisms and therapeutic targets leading to DNA damage 3.1 Experimental materials
[0145] PDD (PDD00017273) was purchased from Selleck, and its corresponding CAS number is 1945950-21-9; MMS was purchased from Sigma; and the plasmid extraction kit was purchased from Promega.
[0146] 3.2 293T cell culture
[0147] The 293T cells were cultured using a conventional 293T cell culture method.
[0148] 3.3 Plasmid construction
[0149] (1) Obtain the target DNA fragment, and use two endonucleases for digestion after PCR amplification. The reaction system is: 5μL CutSmart buffer, 10μg PCR product, 1.5μL restriction endonuclease 1, 1.5μL restriction endonuclease 2, and add water to 50μL. (2) Use the same endonuclease to digest the vector backbone. The reaction system is: 5μL CutSmart buffer, 3μg backbone to be digested, 1μL restriction endonuclease 1, 1μL restriction endonuclease 2, and add water to 50μL. (3) The digestion reaction system is placed in a 37℃ water bath for 1.5-3 hours. (4) The digested product is subjected to agarose gel electrophoresis. The agarose gel containing the target band is stolen under ultraviolet light, and the DNA of the insert and backbone fragments is purified using a gel recovery kit. (5) Use T4 ligase at room temperature for 1 hour to connect the insert fragment to the plasmid backbone. (6) Take the competent cells stored at -80℃, place them on ice to thaw, add 5-10μL of the connected DNA, mix well and tap, place on ice for 30 minutes, heat shock at 42℃ for 1 minute, and immediately place back on ice for 2 minutes. (7) Add 1mL of non-resistant LB medium (2.5g of tryptone, 1.25g of yeast powder and NaCl, add water to 250mL, stir well, sterilize with high pressure steam, and store at 4℃), culture for 45 minutes, and centrifuge at 1000rpm for 30s at room temperature. (8) Discard the supernatant, spread the bacterial solution on an LB culture plate with ampicillin resistance (LB culture medium contains 100μg / mL 1X ampicillin), place it in a 37℃ incubator for overnight culture, and select monoclonal strains. (9) Use a small tip to pick up a monoclonal colony and add it to 1mL of LB culture medium with ampicillin resistance, and shake it at a constant speed in a 37℃ incubator for 4 hours. (10) When the bacterial solution becomes turbid, take the bacterial solution as a template for PCR and send it for sequencing to determine whether the plasmid DNA sequence is consistent with the target sequence.
[0150] 3.4 Plasmid DNA extraction
[0151] (1) Take 5 mL of overnight cultured bacterial solution, centrifuge at 12,000 rpm for 1 minute to collect the bacteria, and aspirate the residual supernatant. (2) Add 500 μL of Buffer P1 containing RNase A, and vortex until the bacteria are completely resuspended. (3) Immediately add 500 μL of Buffer P2, mix by inverting 10 times, and let stand at room temperature for 3 minutes. (4) Add 500 μL of Buffer N3, mix by inverting 15 times until the blue color disappears and a white flocculent precipitate appears, let stand at room temperature for 10 minutes, and centrifuge at 12,000 rpm for 10 minutes. (5) Transfer the supernatant to a 15 mL centrifuge tube, add 0.3 times the volume of supernatant of isopropanol, and mix by inverting 15 times. (6) Transfer the mixed solution to the adsorption column (pre-add 200 μL of Buffer QB to the adsorption column, centrifuge at 12,000 rpm for 1 minute, and discard the filtrate for later use), centrifuge at 12,000 rpm for 1 minute, and discard the filtrate. (7) Add 500μL Buffer PW1 to the adsorption column, centrifuge at 12000rpm for 1 minute, and discard the filtrate. (8) Add 600μL Buffer PW2 (containing anhydrous ethanol) to the adsorption column, centrifuge at 12000rpm for 1 minute, and discard the filtrate. Repeat once. (9) Return the adsorption column to the collection tube, centrifuge at 12000rpm for 2 minutes, and dry the adsorption column. (10) Place the adsorption column in a new 1.5mL EP tube, add 100μL Endotoxin-free Elution Buffer to the center of the adsorption column membrane, let stand at room temperature for 1 minute, centrifuge at 12000rpm for 1 minute, retain the plasmid DNA in the EP tube, and discard the adsorption column. (11) Measure the concentration and quality of plasmid DNA using a spectrophotometer, and store the extracted plasmid DNA at -20℃ for future use.
[0152] 3.5 Cell transfection
[0153] (1) Plate 293T cells in a 6-well plate one day in advance to ensure that the cells reach 70-80% confluence during transfection. (2) Dilute the required amount of plasmid DNA (1 μg) or siRNA (20 nM final concentration) to 100 μL with Opti-MEM. At the same time, in another tube, dilute Lipofectamine 2000 (5 μL) to 100 μL with Opti-MEM and let it stand for 5 minutes. (3) Slowly add the diluted Lipofectamine 2000 to the solution containing DNA or siRNA, mix gently and let it stand for 20 minutes to form a DNA or siRNA-Lipofectamine 2000 complex. (4) Before transfection, aspirate the culture medium in the 6-well plate and replace it with Opti-MEM culture medium, about 1 mL per well. (5) Slowly add the DNA or siRNA-Lipofectamine 2000 complex to the cells and gently shake the plate to ensure mixing. (6) Return the cells to 37°C, 5% CO 2 Incubate in an incubator for 6 hours. Replace the medium containing the transfection complex with high-glucose DMEM medium containing 10% FBS to provide nutrition and maintain cell growth. (7) Continue culturing for 24-48 hours and perform subsequent analysis according to the experimental design, such as protein expression, gene silencing effect, etc.
[0154] 3.6 Co-immunoprecipitation
[0155] (1) Remove the culture medium from the culture dish and wash twice with pre-cooled PBS. (2) Add 1 mL of 0.25% trypsin-EDTA solution, incubate at room temperature for 1 minute, and transfer the cells to a 1.5 mL EP tube. Centrifuge at 300g for 5 minutes. Discard the supernatant and add 0.4 mL of IP lysis buffer (50 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 10% glycerol, freshly added protease inhibitors and phosphatase inhibitors, and IP lysis buffer at a ratio of 1:100). After pipetting to mix, place on ice for 10 minutes. (3) Use a syringe with an 18-22G needle to repeatedly aspirate the lysis buffer more than 10 times to further lyse the cells. Continue lysing on ice for 10 minutes. (4) Centrifuge at 15,000 rpm for 20 minutes and transfer the supernatant to a new EP tube to obtain the protein lysate. If not used immediately, it can be stored in a -80℃ refrigerator. (5) Take the required amount of protein lysate (keep 1 / 10 or 1 / 20 as input), add 1 μL antibody and mix with 30 μL Protein G agarose beads, and rotate at 4°C overnight. (6) After overnight incubation, centrifuge at 7500 rpm for 5 minutes at 4°C. Discard the supernatant and wash 3-5 times with 1 mL IP lysate, each time at 7500 rpm, 4°C for 5 minutes. (7) Discard the supernatant of the last wash, add 30 μL 2X SDS lysate (β-mercaptoethanol: bromophenol blue = 4:1), and heat at 98°C for 10 minutes. (8) Protein electrophoresis detection.
[0156] 3.7 Western Blot
[0157] As described in Example 1.
[0158] 3.8 Cell viability assessment
[0159] (1) Use Dispase enzyme to digest cells and prepare cell suspension. (2) Inoculate an equal number of cells in a 96-well plate to ensure that the total liquid volume in each well is 100 μL, and set up 3-5 replicates for each sample. (3) Place in a cell culture incubator for 2-4 hours. After the cells adhere to the wall, add 10 μL of CCK-8 solution to each well and mix gently to avoid the formation of bubbles. (4) Place the 96-well plate in the incubator and continue incubating for 2 hours, then use an ELISA reader to detect the absorbance at 450 nm.
[0160] 3.9 Statistical analysis
[0161] As described in Example 1.
[0162] 3.10 Experimental Results
[0163] 3.10.1MORC2 S87L-MNs, MORC2 Q400R -MNs and MORC2 D466N - Downregulation of PARP1 expression and reduction of activated PAR in MNs
[0164] After PARP1 recognizes DNA damage, it rapidly PARylates PARP1 itself, histones, and certain chromatin-related proteins, which can serve as scaffolds for the early recruitment of DDR factors for DNA repair. In order to explore the role of PARP1 and PARylation in abnormal DNA damage repair caused by MORC2 pathogenic variants, we used WB to detect the levels of MORC2, PARP1, and overall PAR in MNs of each group, and detected the neuron-specific marker TUJ1 to reflect neuronal development. The results showed that compared with the Control group, the MORC2 and PARP1 protein levels in the MORC2 pathogenic variant group were downregulated ( Fig. 20 A, B), PAR reduction ( Fig.21 A, B), and TUJ1 expression was downregulated (( Fig. 22 A, B). In summary, MORC2 pathogenic variants can cause downregulation of PAPR1 protein and reduced PARylation, leading to neuronal developmental arrest.
[0165] 3.10.2 MORC2 after MMS-induced DNA damage S87L -MNPs, MORC2 Q400R -MNPs and MORC2 D466N -PAR of MNPs was significantly downregulated
[0166] DNA damage stress was increased at the MNP stage, and methyl methanesulfonate (MMS) 200 μM was used to induce DNA double-strand breaks. After 36 hours of treatment, the level of PARylation protein closely related to DNA repair in the MORC2 pathogenic variant group was significantly downregulated compared with the Control group ( Fig.23 A, B), suggesting MORC2 S87L -MNPs, MORC2 Q400R -MNPs and MORC2 D466N -MNPs have a weakened ability to cope with DNA damage stress, which may be one of the main reasons for the subsequent accumulation of DNA damage.
[0167] 3.10.3MORC2 S87L 、MORC2 Q400R 、MORC2 D466N Protein-PAPR1 interaction weakened
[0168] Previous studies have shown that the DNA repair effector protein PARP1 interacts with the MORC2 protein and can jointly promote DNA repair in subsequent DNA damage responses. In order to explore whether MORC2 pathogenic variants affect the MORC2 / PARP1 interaction, we constructed plasmids carrying MORC2-WT, MORC2-p.S87L, MORC2-p.Q400R, and MORC2-p.D466N, overexpressed the above plasmids in 293T cells, and then used immunoprecipitation technology to detect the MORC2 / PARP1 interaction. The results showed that compared with the wild-type MORC2 protein, the binding of MORC2 carrying pathogenic variants to PARP1 was significantly reduced ( Fig.24 ). Tip MORC2 S87L 、MORC2 Q400R 、MORC2 D466N The mutation weakened the interaction between MORC2 protein and PAPR1.
[0169] 3.10.4PDD can improve DNA damage and axonal degeneration in MORC2S87L-MNs, MORC2Q400R-MNs, and MORC2D466N-MNs
[0170] In order to explore the potential therapeutic effects of two small molecules, PAR hydrolase (PARG) inhibitor (PDD) and NMN, on CMT2Z caused by MORC2 pathogenic variants, the effects of PDD and NMN on neuronal morphology and DNA damage repair-related indicators were observed in each group of MNs. First, we used CCK8 to detect the activity of MNs after 48 hours of action of different concentrations of PDD and NMN to determine the optimal drug concentration. The results showed that MNs had the best activity when the PDD concentration was 0.5μM, and MNs had the best activity when the NMN concentration was 500μM ( Fig.25 ), therefore, in subsequent studies, we used a PDD working concentration of 0.5 μM and a NMN working concentration of 500 μM. + MNs stage), PDD and NMM were added to each group, and one week later, CHAT + At the MNs stage, TUJ1 immunofluorescence staining was used to mark neurons to observe the growth of MNs. The results showed that compared with the MNs in the groups without PDD, the neurite length and branching of Control-MNs did not change significantly after PDD intervention, while MORC2 S87L -MNs, MORC2 Q400R -MNs and MORC2 D466N -MNs had an increased average neurite length and an increased number of neurite branches, with MORC2 S87L -MNs are most prominent ( Fig.26); Compared with the MNs in the groups without NMN, after NMN intervention, the neurites and branches of the neurons in the Control-MNs did not change significantly, and MORC2 S87L -MNs, MORC2 Q400R -MNs and MORC2 D466N -MNs showed an increasing trend in the average neurite length and neurite branching ( Fig. 27 ), but not to the same extent as in the PDD-treated group. The results showed that PDD treatment could significantly improve the morphological abnormalities of MNs caused by MORC2 mutation. After 1 week of drug treatment, whole-cell proteins were collected, and WB was used to detect the PAR level and the expression of DNA damage marker γH2AX in MNs. The results showed that compared with the PDD-untreated group, MORC2 S87L -MNs and MORC2 Q400R -MNs had significantly increased PAR levels, compared with Control-MNs and MORC2 D466N Compared with the PDD-untreated group, MORC2 S87L -MNs showed a significant downregulation of the DNA damage marker γH2AX, while Control-MNs and MORC2 Q400R -MNs have an increasing trend of γH2AX, MORC2 D466N -MNs had no significant changes in γH2AX ( Fig.28 AC). In summary, PDD can upregulate PAR levels, reduce DNA damage accumulation, and reduce the damage of MORC2 pathogenic variants to MNs. In summary, PDD can improve MORC2 S87L -MNs, MORC2 Q400R -MNs and MORC2 D466N -DNA damage and axonal degeneration of MNs, that is, the PDD can be used as a potential therapeutic drug for Charcot-Marie-Tooth disease.
Claims
1. Use of a PAR hydrolase inhibitor in the preparation of a medicament for treating and / or preventing Charcot-Marie-Tooth disease.
2. The use according to claim 1, characterized in that: The PAR hydrolase inhibitors include PDD00017273, ethacridine lactate, PDD00031705, COH34, PDD00017238, JA2131, PDD00017272, PARG-IN-4 and / or ethacridine; Optionally, the PAR hydrolase inhibitor is PDD00017273.
3. The use according to claim 1, characterized in that: The Charcot-Marie-Tooth Disease includes demyelinating Charcot-Marie-Tooth Disease, axonal Charcot-Marie-Tooth Disease and / or intermediate Charcot-Marie-Tooth Disease; Optionally, the Charcot-Marie-Tooth disease is axonal Charcot-Marie-Tooth disease; Optionally, the drug further comprises a pharmaceutically acceptable excipient; Optionally, the pharmaceutically acceptable excipients include diluents, binders, surfactants, humectants, adsorbent carriers, lubricants, fillers and / or disintegrants; Optionally, the dosage form of the drug includes injection, tablet, capsule, powder, granule, ointment, suppository, inhalant, gel, microsphere and / or aerosol.
4. A pharmaceutical composition for treating and / or preventing Charcot-Marie-Tooth disease, characterized in that: The pharmaceutical composition comprises a therapeutically and / or prophylactically effective amount of a PAR hydrolase inhibitor.
5. The pharmaceutical composition according to claim 4, characterized in that The PAR hydrolase inhibitors include PDD00017273, ethacridine lactate, PDD00031705, COH34, PDD00017238, JA2131, PDD00017272, PARG-IN-4 and / or ethacridine; Optionally, the PAR hydrolase inhibitor is PDD00017273; Optionally, the Charcot-Marie-Tooth disease includes demyelinating Charcot-Marie-Tooth disease, axonal Charcot-Marie-Tooth disease and / or intermediate Charcot-Marie-Tooth disease; Optionally, the Charcot-Marie-Tooth disease is axonal Charcot-Marie-Tooth disease.
6. A pharmaceutical preparation for treating and / or preventing Charcot-Marie-Tooth disease, characterized in that: The pharmaceutical preparation comprises the pharmaceutical composition according to claim 4 or 5.
7. The pharmaceutical preparation according to claim 6, characterized in that The dosage form of the pharmaceutical preparation includes a dosage form for enteral administration or a dosage form for parenteral administration; Optionally, the dosage form for administration through the gastrointestinal tract includes solutions, granules, tablets, capsules, suspensions, powders, sustained-release preparations, effervescent preparations, emulsions, syrups, drops and / or chewable preparations; Optionally, the non-intestinal administration dosage form includes an injection dosage form, a respiratory tract administration dosage form, a cavity administration dosage form, a mucosal administration dosage form and / or a skin administration dosage form.
8. Any of the following methods, characterized in that The method comprises: (1) A method for inhibiting axonal degeneration of motor neurons (MNs) with MORC2 mutations in vitro for non-therapeutic purposes, the method comprising administering an effective amount of a PAR hydrolase inhibitor according to any one of claims 1 to 3 to a cell system in need thereof; (2) An in vitro non-therapeutic method for reducing DNA damage in MNs after MORC2 mutation, the method comprising administering an effective amount of the PAR hydrolase inhibitor described in any one of claims 1 to 3 to a cell system in need thereof.
9. The method according to claim 8, characterized in that The MORC2 mutation-induced MNs include MORC2 S87L -MNs, MORC2 Q400R -MNs and / or MORC2 D466N -MNs; Optionally, the reducing DNA damage in MNs after MORC2 mutation comprises reducing the expression of DNA damage markers and / or increasing the expression of DNA repair proteins; Optionally, the DNA damage marker includes γH2AX; Optionally, the DNA repair protein comprises BRCA1, RAD51 and / or DNA-PKc.
10. Use of the PAR hydrolase inhibitor according to any one of claims 1 to 3 in the preparation of a medicament for improving axonal degeneration and / or reducing DNA damage in Charcot-Marie-Tooth disease.
